Mia A. Jorgensen
Herlev, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
Journal: Journal for immunotherapy of cancer
Published: November 06, 2022
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.
Journal: Journal for immunotherapy of cancer
Published: September 22, 2022
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment.
Journal: Oncoimmunology
Published: February 03, 2022
The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.
Journal: Oncoimmunology
Published: September 14, 2020
Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.
Journal: Cancer immunology, immunotherapy : CII
Published: May 29, 2019
Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation.
Journal: Oncoimmunology
Published: March 20, 2018
Peptidyl arginine deiminase inhibitor effect on hepatic fibrogenesis in a CCl4 pre-clinical model of liver fibrosis.
Journal: American journal of translational research
Published: April 02, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026